Multiple Sclerosis Disease-Modifying Therapies

The disease-modifying therapies (DMTs) for multiple sclerosis are one of the great success stories of modern neurology: in three decades the field has gone from a single moderately effective injectable to a deep menu of oral pills and high-efficacy monoclonal antibodies. Yet the menu is only useful if you understand two things about every agent — how it tames the immune system and what signature harm it can cause in exchange. That trade-off is the entire game in MS pharmacology. The most important framing to carry into every conversation: DMTs are preventive. They reduce relapses, suppress new MRI lesions, and slow disability accrual in relapsing MS — but they do not treat an attack that is already underway. This page organizes the agents by efficacy tier, anchors each to its mechanism, and pairs it with the risk you must monitor for.

What DMTs Do — and What They Don't

A DMT works in the background, lowering the long-run rate of inflammatory events. It does nothing for the patient sitting in front of you in the middle of an acute relapse. Keep the two jobs separate:

• Acute relapse → high-dose corticosteroids (typically IV or high-dose oral methylprednisolone) to shorten the attack; plasma exchange (PLEX) is the rescue option for steroid-refractory, severe relapses. Steroids speed recovery but do not change the long-term course.
• Long-term disease control → a DMT, chosen by efficacy tier, risk tolerance, disease activity, and patient factors (family planning, comorbidities, JC virus status, monitoring feasibility).
• Treatment philosophy: the field has shifted decisively toward early, effective treatment. Rather than starting low and escalating only after breakthrough activity, many clinicians now favor higher-efficacy therapy up front in patients with active or prognostically worrisome disease, because irreversible axonal loss accrues early.

Relapsing vs. Progressive Disease

DMTs are most effective against the focal inflammatory biology that drives relapses and gadolinium-enhancing lesions — the hallmark of relapsing-remitting MS (RRMS) and active secondary progressive MS. They are far less effective against the smoldering, neurodegenerative process of progressive disease, where inflammation recedes and axonal degeneration dominates. Two agents have specifically earned ground in progressive disease: ocrelizumab is approved for primary progressive MS (PPMS), and siponimod is used in active secondary progressive MS. For most progressive patients without ongoing relapse activity, the benefit of any DMT is modest, and rehabilitation and symptom management carry much of the load.

Moderate-Efficacy "Platform" Injectables

These were the first DMTs and remain the safest. Efficacy is modest, but the safety profile is benign and they carry no PML risk — a reason they still suit pregnancy planning and lower-activity disease.

• Interferon-beta (IFN-β-1a, IFN-β-1b; immunomodulatory, shifts cytokine balance and limits lymphocyte trafficking) — signature issues: flu-like symptoms after injection, injection-site reactions, and transaminitis; monitor liver enzymes and CBC.
• Glatiramer acetate (a random polymer of four amino acids that acts as a decoy/immune modulator, shifting T-cells toward a regulatory phenotype) — signature issues: injection-site reactions (including lipoatrophy) and a rare, self-limited immediate post-injection systemic reaction (flushing, chest tightness, palpitations) that is benign and resolves spontaneously. No routine lab monitoring required.

Oral Agents

The orals transformed adherence and span a wide efficacy range. Each class has a distinct mechanism and a distinct monitoring burden.

• S1P receptor modulators — fingolimod, siponimod, ozanimod, ponesimod (modulate the sphingosine-1-phosphate receptor, trapping lymphocytes in lymph nodes so they cannot egress to the CNS; the newer, more receptor-selective members — ozanimod and ponesimod — have since been approved) — signature risks: first-dose bradycardia and AV conduction block (fingolimod classically requires first-dose cardiac monitoring; siponimod and ozanimod use dose titration), macular edema (baseline and on-treatment eye exams), lymphopenia, and infection risk including rare PML. Confirm varicella immunity before starting; siponimod requires CYP2C9 genotyping.
• Dimethyl fumarate (and the related diroximel/monomethyl fumarate; activates the Nrf2 antioxidant pathway with broader immunomodulatory effects) — signature risks: flushing and GI upset (often early and self-limited), and lymphopenia — sustained, severe lymphopenia confers a small PML risk, so monitor lymphocyte counts.
• Teriflunomide (inhibits dihydroorotate dehydrogenase, blocking de novo pyrimidine synthesis in rapidly dividing lymphocytes) — signature risks: teratogenicity (boxed warning; requires reliable contraception and, when needed, an accelerated cholestyramine elimination protocol given its long half-life), hepatotoxicity (monitor LFTs), and hair thinning.
• Cladribine (a purine analog that selectively depletes B and T lymphocytes, given as short oral courses over two years for a durable effect) — signature risks: lymphopenia, infection (including herpes zoster), and a theoretical malignancy concern; baseline infection and pregnancy screening required.

High-Efficacy Monoclonal Antibodies

This is the top tier — the most potent suppression of relapses and new lesions, and increasingly the first choice in highly active disease. Potency comes at the cost of more serious, mechanism-specific harms.

• Natalizumab (anti-α4-integrin / VLA-4 monoclonal antibody; blocks lymphocyte adhesion and entry across the blood-brain barrier into the CNS) — among the most effective DMTs available. Signature risk: progressive multifocal leukoencephalopathy (PML) from JC virus reactivation. Risk is stratified by three factors — JC virus antibody status (and titer/index), prior immunosuppressant use, and treatment duration beyond ~2 years — which together guide whether and how long to treat, with periodic JCV serology and MRI surveillance.
• Anti-CD20 B-cell depletion — ocrelizumab, ofatumumab, ublituximab (and rituximab off-label; monoclonal antibodies that deplete CD20-positive B lymphocytes; the subcutaneous anti-CD20 ofatumumab and the IV anti-CD20 ublituximab have since been approved) — highly effective; ocrelizumab is notably approved for primary progressive MS, the first DMT to earn that indication. Ocrelizumab is IV; ofatumumab is a self-administered subcutaneous injection. Signature risks: infusion/injection reactions, infections (including reactivation of hepatitis B — screen first), and hypogammaglobulinemia with prolonged use; vaccinate before starting.
• Alemtuzumab (anti-CD52 monoclonal antibody; profound depletion of T and B lymphocytes followed by immune reconstitution, given as two short annual courses) — very high efficacy but a fraught safety profile that has relegated it to a reserved/restricted role. Signature risk: delayed secondary autoimmunity during immune reconstitution — classically thyroid disease (Graves'), immune thrombocytopenia (ITP), and autoimmune nephropathy (anti-GBM disease) — plus infusion reactions and infection. Mandates prolonged scheduled monitoring after the last dose: monthly CBC with differential, serum creatinine, and urinalysis, plus thyroid function tests every 3 months, continued until 48 months after the last infusion.

Efficacy Tier, Mechanism, and Signature Risk

Monitoring: The Price of Potency

Every DMT comes with a monitoring schedule keyed to its signature risk, and skipping it is where harm slips through. Map each agent to its surveillance and the table above almost reads itself:

• Before starting: baseline CBC and LFTs broadly; JC virus serology before/during natalizumab; hepatitis B (and consider TB) screening before anti-CD20 agents; varicella immunity before S1P modulators; CYP2C9 genotype before siponimod; pregnancy status and contraception before teriflunomide and cladribine; bring vaccinations up to date before immunosuppression.
• First dose: cardiac monitoring with fingolimod (bradycardia/AV block).
• On treatment: serial lymphocyte counts (S1P modulators, dimethyl fumarate, cladribine), LFTs (interferon, teriflunomide), ophthalmologic exams (S1P modulators — macular edema), prolonged monthly blood and urine monitoring after alemtuzumab (autoimmunity), and routine surveillance MRI to detect subclinical activity or early PML.

Pearl: when a board question pairs a drug with a complication, it is almost always testing the signature risk — bradycardia with fingolimod, PML with natalizumab, secondary autoimmunity with alemtuzumab, teratogenicity with teriflunomide. Learn the one-to-one mapping and the rest falls into place.